Methodological challenges in benefit risk for small patient populations Methodological Challenges in Benefit Risk for Small Patient Populations The increasing focus on the assessment of benefit-risk profiles in pharmacovigilance has become particularly important for small patient populations in areas like biosimilars, vaccines, ATMPs (Advanced Therapy Medicinal Products), and specialty products. This article outlines the regulatory expectations and methodological considerations that must be taken into account when evaluating these products, especially given the unique challenges posed by rare diseases and limited patient cohorts. 1. Understanding the Regulatory Framework for Benefit-Risk Assessment Benefit-risk assessment is a fundamental component of drug development and…

Real world data sources to support PV in rare and ultra rare indications Real World Data Sources to Support Pharmacovigilance in Rare and Ultra Rare Indications Pharmacovigilance (PV) plays a critical role in ensuring the safety of medical products, especially in rare and ultra-rare indications. This tutorial provides a comprehensive step-by-step guide for pharmaceutical professionals involved in the development and post-market monitoring of biosimilars, vaccines, advanced therapy medicinal products (ATMPs), and specialty products. We will explore various real-world data (RWD) sources, their applications, and how they can be leveraged to enhance PV initiatives. 1. Understanding Pharmacovigilance and Its Importance Pharmacovigilance…

PV agreements and SDEAs specific to biosimilars and ATMP partnerships Understanding Pharmacovigilance Agreements and SDEAs in Biosimilars and ATMP Partnerships As the biotechnology landscape evolves, the importance of effective pharmacovigilance (PV) practices becomes critical, especially in the context of biosimilars and advanced therapy medicinal products (ATMPs). This tutorial aims to guide pharmaceutical professionals through the intricacies of PV agreements and Safety Data Exchange Agreements (SDEAs), shedding light on regulations, best practices, and international standards. 1. Introduction to Pharmacovigilance and Its Significance for Biosimilars and ATMPs Pharmacovigilance is essential for ensuring the safety of pharmaceutical products, encompassing the collection, analysis, monitoring,…

Global alignment of PV strategies for vaccines across US EU and WHO Global alignment of PV strategies for vaccines across US EU and WHO Pharmacovigilance (PV) plays a critical role in ensuring drug safety throughout a product’s life cycle, particularly for vaccines, biosimilars, advanced therapy medicinal products (ATMPs), and specialty products. This regulatory tutorial aims to provide a comprehensive understanding of the pharmacovigilance strategies for vaccines that are harmonized across the United States, European Union, and World Health Organization. By emphasizing key components such as adverse event following immunization (AEFI), traceability, and safety registries, this article will support Pharma professionals,…

Future PV Trends in Cell, Gene, and Personalised Medicines The field of pharmacovigilance (PV) is rapidly evolving, particularly in the context of innovative therapies such as cell, gene, and personalised medicines. This article provides a step-by-step tutorial for professionals in pharmaceuticals, regulatory affairs, and clinical operations to navigate the ongoing changes in PV systems, focusing on biosimilars, vaccines, Advanced Therapy Medicinal Products (ATMPs), and specialty products. The guidance is relevant to stakeholders in the US, UK, and EU, highlighting best practices and regulatory compliance. Understanding Pharmacovigilance in Contemporary Medicine Pharmacovigilance is the science that aims to improve patient safety and…

How inspectors review PV for ATMPs, vaccines and gene therapies How inspectors review PV for ATMPs, vaccines and gene therapies Understanding Pharmacovigilance (PV) for Advanced Therapy Medicinal Products (ATMPs), Vaccines, and Gene Therapies Pharmacovigilance (PV) is a critical component of the drug lifecycle, particularly for Advanced Therapy Medicinal Products (ATMPs), vaccines, and gene therapies. The regulatory landscape for these products is characterized by their complexity and the unique safety profiles they present. This tutorial provides an in-depth overview of how inspectors review Pharmacovigilance systems and practices in compliance with FDA regulations, as well as relevant considerations for the UK and…

Governance for Cross Functional Oversight of High Risk Specialty Product PV Governance for Cross Functional Oversight of High Risk Specialty Product PV Pharmacovigilance (PV) is a critical component in ensuring patient safety and effective product lifecycle management. For high-risk specialty products such as biosimilars, vaccines, and advanced therapy medicinal products (ATMPs), robust governance structures are essential for effective cross-functional oversight. This article aims to provide a comprehensive, step-by-step regulatory tutorial on establishing such governance frameworks, with a particular focus on the U.S. Food and Drug Administration (FDA) requirements and a comparative view of EU/UK regulations. Understanding the Regulatory Landscape for…

Periodic Reporting Requirements for Vaccines, ATMPs, and Biosimilars Understanding Periodic Reporting Requirements for Vaccines, ATMPs, and Biosimilars Pharmacovigilance is an essential component of drug and biological product safety, particularly for complex therapies such as vaccines, Advanced Therapy Medicinal Products (ATMPs), and biosimilars. Regulatory expectations regarding periodic reporting are pivotal for maintaining compliance and ensuring patient safety. This article provides a comprehensive step-by-step guide to understanding and implementing the reporting requirements mandated by the US FDA, with comparisons to EU and UK regulations where relevant. 1. Introduction to Pharmacovigilance Requirements Pharmacovigilance encompasses all activities aimed at monitoring the safety of medicinal…

Training HCPs and Sites on AE Reporting for Novel and Complex Products Pharmacovigilance (PV) is a critical component of drug safety that ensures the evaluation, monitoring, and prevention of adverse events associated with pharmaceutical products. This is particularly important for novel and complex products such as biosimilars, vaccines, advanced therapy medicinal products (ATMPs), and specialty products that may carry unique safety concerns. Training healthcare professionals (HCPs) and clinical trial sites on adverse event (AE) reporting is essential to maintain patient safety and regulatory compliance. This tutorial outlines the step-by-step approach to effectively train these stakeholders on AE reporting in accordance…

Managing lot level and batch specific safety issues in biologics and vaccines Managing Lot Level and Batch Specific Safety Issues in Biologics and Vaccines Pharmacovigilance in the context of biologics, including biosimilars, vaccines, advanced therapy medicinal products (ATMPs), and specialty products, is a critical focus for regulatory agencies worldwide. It ensures the ongoing safety, efficacy, and risk management of medicinal products after they have been approved for market use. This comprehensive step-by-step guide is intended for pharma professionals, clinical operations experts, and regulatory affairs specialists who seek to understand and manage lot-level and batch-specific safety issues effectively in the US,…